Endovastec(SH:688016) Sou Hu Cai Jing·2025-12-05 12:21Core Viewpoint - The stock of Xinmai Medical (688016) has shown a slight increase, with a closing price of 93.18 yuan on December 5, 2025, reflecting a 1.28% rise, while the overall market sentiment indicates a mixed flow of funds among different investor categories [1][2]. Financial Performance - For the first three quarters of 2025, Xinmai Medical reported a main business revenue of 1.015 billion yuan, a year-on-year increase of 4.66% [3]. - The net profit attributable to shareholders was 429 million yuan, representing a year-on-year decline of 22.46% [3]. - The company's gross profit margin stands at 70.4%, significantly higher than the industry average of 51.22% [3]. - The net profit margin is 41.69%, which is substantially above the industry average of 9.57% [3]. Market Position - Xinmai Medical's total market capitalization is 11.486 billion yuan, slightly above the industry average of 11.035 billion yuan [3]. - The company ranks 16th in net profit within the medical device industry, with a price-to-earnings ratio of 20.08, which is considerably lower than the industry average of 64.34 [3]. Recent Trading Activity - On December 5, 2025, the net outflow of main funds was 442.24 million yuan, accounting for 5.52% of the total transaction amount [1][2]. - Retail investors showed a net inflow of 544.67 million yuan, representing 6.80% of the total transaction amount on the same day [1][2]. Analyst Ratings - In the last 90 days, 9 institutions have rated Xinmai Medical, with 7 buy ratings and 2 hold ratings, indicating a generally positive outlook [4]. - The average target price set by analysts over the past 90 days is 136.03 yuan [4].